Feedback / Questions
temozolomide/perillyl alcohol conjugate (NEU001) - NeOnc Technologies, NeuCen BioMed
https://www.globenewswire.com/news-release/2025/09/10/3147781/0/en/NeOnc-Technologies-Receives-FDA-Authorization-to-Proceed-with-Phase-II-Clinical-Trial-of-NEO212-A-First-in-Class-Oral-Chemical-Conjugated-Chemotherapy-Candidate-for-Brain-Cancer.html
Sep 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next